Immedica Drug Patent Portfolio
Immedica owns 1 orange book drug protected by 11 US patents Given below is the list of Immedica's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12115169 | Ganaxolone For Use In Treating Tuberous Sclerosis Complex And Seizure Disorders | 30 Sep, 2042 | Active |
| US12268696 | Ganaxolone For Use In Treating Tuberous Sclerosis Complex And Seizure Disorders | 30 Sep, 2042 | Active |
| US10603308 | Methods and compositions for treatment of epileptic disorders | 10 Aug, 2037 | Active |
| US12144801 | Methods and compositions for treatment of epileptic disorders | 10 Aug, 2037 | Active |
| US8318714 | Liquid ganaxolone formulations and methods for the making and use thereof | 28 Nov, 2031 | Active |
| US7858609 | Solid ganaxolone formulations and methods for the making and use thereof | 28 Nov, 2026 | Active |
| US8022054 | Liquid ganaxolone formulations and methods for the making and use thereof | 28 Nov, 2026 | Active |
| US8367651 | Solid ganaxolone formulations and methods for the making and use thereof | 28 Nov, 2026 | Active |
| US8618087 | Solid ganaxolone formulations and methods for the making and use thereof | 28 Nov, 2026 | Active |
| US9029355 | Solid ganaxolone compositions and methods for the making and use thereof | 28 Nov, 2026 | Active |
| US9056116 | Liquid ganaxolone formulations and methods for the making and use thereof | 28 Nov, 2026 | Active |
Latest Legal Activities on Immedica's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Immedica.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate | 17 Feb, 2026 | US8318714 |
| Email Notification | 26 Sep, 2025 | US12144801 |
| Email Notification | 26 Sep, 2025 | US10603308 |
| Change in Power of Attorney (May Include Associate POA) | 26 Sep, 2025 | US12144801 |
| Change in Power of Attorney (May Include Associate POA) | 26 Sep, 2025 | US10603308 |
| Notice of Final Determination -Eligible | 05 Jun, 2025 | US8318714 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US8318714 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8318714 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 08 May, 2025 | US8618087 |
| Email Notification | 09 Apr, 2025 | US12268696 |
| Patent eGrant Notification | 08 Apr, 2025 | US12268696 |
| Mail Patent eGrant Notification | 08 Apr, 2025 | US12268696 |
| Patent Issue Date Used in PTA Calculation | 08 Apr, 2025 | US12268696 |
| Recordation of Patent eGrant | 08 Apr, 2025 | US12268696 |
| Recordation of Patent Grant Mailed | 08 Apr, 2025 | US12268696 |
Immedica's Family Patents
Immedica drugs have patent protection in a total of 15 countries. It's US patent count contributes only to 48.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Immedica Drug List
Given below is the complete list of Immedica's drugs and the patents protecting them.
1. Ztalmy
Ztalmy is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12115169 | Ganaxolone For Use In Treating Tuberous Sclerosis Complex And Seizure Disorders |
30 Sep, 2042
(16 years from now)
| Active |
| US12268696 | Ganaxolone For Use In Treating Tuberous Sclerosis Complex And Seizure Disorders |
30 Sep, 2042
(16 years from now)
| Active |
| US10603308 | Methods and compositions for treatment of epileptic disorders |
10 Aug, 2037
(10 years from now)
| Active |
| US12144801 | Methods and compositions for treatment of epileptic disorders |
10 Aug, 2037
(10 years from now)
| Active |
| US8318714 | Liquid ganaxolone formulations and methods for the making and use thereof |
28 Nov, 2031
(5 years from now)
| Active |
| US7858609 | Solid ganaxolone formulations and methods for the making and use thereof |
28 Nov, 2026
(3 months from now)
| Active |
| US8022054 | Liquid ganaxolone formulations and methods for the making and use thereof |
28 Nov, 2026
(3 months from now)
| Active |
| US8367651 | Solid ganaxolone formulations and methods for the making and use thereof |
28 Nov, 2026
(3 months from now)
| Active |
| US8618087 | Solid ganaxolone formulations and methods for the making and use thereof |
28 Nov, 2026
(3 months from now)
| Active |
| US9029355 | Solid ganaxolone compositions and methods for the making and use thereof |
28 Nov, 2026
(3 months from now)
| Active |
| US9056116 | Liquid ganaxolone formulations and methods for the making and use thereof |
28 Nov, 2026
(3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ztalmy's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List